Search PubMed⌕ Search

Biomedical subjects

Jeff Q Bostic

Publications and source records attributed to Jeff Q Bostic.

14 recordsLinked to original sources
PubMed2006

Target-symptom psychopharmacology: between the forest and the trees.

Psychopharmacology practice seeks to fit specific treatments to specific disease processes. Although categorical diagnoses have improved focus on observable symptom constellations, these approximately 300 categories have limited benefits for illuminating underlying disease pathophysiology. Existing medications do not couple well to the symptom constellations of given disorders. Rather, current medications ameliorate symptoms overlapping among various disorders. Harnessing technology to identify a patient's wider symptom constellation, prioritizing and targeting symptoms across disorders, considering symptoms more dimensionally instead of "present or not," and eliciting factors necessary to improve adherence may allow medication selections to be tailored better to individual patients.

Adolescent↗
PubMed2006

An update on pharmacologic treatments for autism spectrum disorders.

Increasingly recognized over the past 20 years, autism spectrum disorders (ASD) are heterogeneous. Medication treatments remain fundamentally ameliorative, so prioritizing symptoms and matching medications to the patient's constellation of symptoms remains the psychopharmacologic approach to ASD. Atypical antipsychotic medications and glutamatergic agents are receiving increased attention, and antidepressants are being examined for specific symptoms and for younger patients who have autism. Large multisite networks (Research Units on Pediatric Psychopharmacology; Studies to Advance Autism Research and Treatment) have been constructed to expedite studies to elucidate effective treatments for ASD. Findings from these networks are coupled with those from recent independent trials.

Antidepressive Agents↗
PubMed2006

Generation Rx.

Explore the source record for details and available documents.

Child↗
PubMed2005

The functional assessment of media in child and adolescent psychiatric treatment.

Clinicians and parents share a responsibility to educate themselves in how young people communicate with each other and how it impacts on communication with the adults in their lives. The greater fluency that clinicians have with the world of youth, the easier it is to begin a meaningful dialogue with young people. Such a dialogue always has been the purview of clinicians interested in the developmental trajectory of their young patients. The enormity of media exposure and the changes that characterize current media formats make such a dialogue important and challenging. From watching video clips to listening to music, this assessment affords clinicians a snapshot into the milieu of the modern young world. The dialogue is "virtually" always well worth the effort.

Adolescent↗
PubMed2005

Treatment of depression in children and adolescents.

Depression occurs in children and adolescents, although it may appear differently in younger patients. Research suggests juvenile depression may respond to psychotherapy and to pharmacologic agents, and that antidepressants remain a valuable treatment for juveniles with depression. Diagnostic considerations in juveniles with mood symptoms are discussed. A brief overview is provided of the evidence supporting psychotherapy for juveniles with depression. Controlled antidepressant trials in juveniles with depression provide some support for the use of some selective serotonin reuptake inhibitors and little support for atypical antidepressants, tricyclic antidepressants, or monoamine oxidase inhibitors. Evidence from suicide rates over time, autopsy findings among juvenile suicides, and impacts of antidepressant prescribing trends are related to the current controversy over suicidality and antidepressant use in juvenile patients. Based on this evidence, practical guidelines for treatment of juvenile depression are provided.

Adolescent↗
PubMed2005

Autism spectrum disorders: emerging pharmacotherapy.

Autism, Asperger and other pervasive developmental disorders (PDDs) are an increasingly commonly identified group of conditions wherein patients experience significant difficulty in social interactions, communicating with others, and inflexible adherence to unusual, unhelpful and frequently stereotyped routines and behaviour. These autism spectrum disorders are now being diagnosed earlier in life (approximately 15 months), and often remain a chronic, daily burden for those afflicted. In addition to the often profound impact on an individual's quality of life, the familial, social and economic burdens of PDDs can be enormous. No treatments are curative, and most pharmacological treatments are employed to treat specific troubling symptoms rather than the core features of the disorder itself. Therefore, more effective pharmacotherapies are desperately needed. This review describes current and emerging pharmacotherapies that may advance care of people with PDDs.

Autistic Disorder↗
PubMed2003

Use of citalopram in pervasive developmental disorders.

This study assessed the effectiveness and tolerability of the selective serotonin reuptake inhibitor citalopram in the treatment of patients with pervasive developmental disorders (PDDs). The medical charts of 15 children and adolescents (aged 6-16 yr) with Asperger syndrome, autism, or PDD not otherwise specified treated with citalopram were retrospectively reviewed. The final dose of citalopram was 16.9 +/- 12.1 mg/day with a treatment duration of 218.8 +/- 167.2 days. Independent ratings of the Clinical Global Impression (CGI) Severity and Improvement scales allowed comparison between baseline and PDD symptoms at the last visit. Eleven adolescents (73%) exhibited significant improvement in PDD, anxiety, or mood CGI score (z = 2.95; p =.003). Anxiety symptoms associated with PDDs improved significantly in 66% of patients (z = 2.83, p =.005), and mood symptoms improved significantly in 47% of patients (z = 2.78, p =.005). Mild side effects were reported by five patients (33%). These data suggest citalopram may be effective, safe, and well tolerated as part of the treatment of PDDs.

Adolescent↗
PubMed2003

From Alice Cooper to Marilyn Manson: the significance of adolescent antiheroes.

Every generation has icons attractive to adolescents and equally repugnant to adults. This article examines antihero characteristics, their appeal to adolescents, and how adults can respond to adolescents enamored of antiheroes. The stage personas of antiheroes champion rejection of the mainstream, assail adult constraints and expectations, explore frightening topics, and ultimately fulfill the adolescent fantasy of surviving alienation and emerging victorious over parents and peers. But antihero idolization also tests the adult's defenses. Adults, fearing loss of control and rejection by the adolescent, sometimes resort to primitive defenses mismatched to the developmental needs of the adolescent. Adults, as much as the adolescents, benefit from examining their individual reactions to the antihero and how their current relationship can accommodate this intrusion. The antihero phenomenon presents adults with an opportunity to model ways to think through that which is uncomfortable and to navigate together the adolescent's developmentally normative separation efforts.

Adolescent↗
PubMed2002

From Elephant Man to Jerry Springer: the rise of the psychological tele-spectacle.

In the circus sideshow, people with physical deformities were exhibited for profit and entertainment. The circus sideshow itself is no longer socially acceptable, but it has taken a different form. Television programs like The Jerry Springer Show make spectacles of psychological afflictions and variations in human behavior. On the one hand, these shows provide participants with attention, recognition, an outlet for masochism, and an identity. To the viewer, they offer both reassurance and an outlet for unacceptable thoughts and feelings. They also explore society's collective subconscious. On the other hand, these shows approximate psychological interventions without concern for the result, have potentially negative consequences for vulnerable viewers, and blur the boundary between fantasy and real life.

Journal Article↗
PubMed2002

Citalopram for the treatment of adolescent anxiety disorders: a pilot study.

Charts of 17 adolescent patients treated naturalistically with citalopram for various anxiety disorders were reviewed. Patients were retrospectively assessed using the Clinical Global Impression (CGI)-Severity scale at the beginning and end of treatment. Eighty-two percent (14/17) of patients were rated as much or very much improved on the CGI-Improvement scale after treatment with citalopram. Patients were treated for an average of 156-/+85.1 days at a mean dose of 32.3-/+18.5 mg/day of citalopram. Fifty-three percent (9/17) of this sample had previous exposure to alternative selective serotonin reuptake inhibitors, and 89% (8/9) of those patients responded positively to citalopram. Citalopram appeared well tolerated, with only one patient discontinuing treatment due to side effects. In this naturalistic setting, citalopram appeared to be a well-tolerated and effective treatment for a range of anxiety disorders in adolescents.

Adolescent↗